Navigation Links
Novavax Announces Manufacturing Management Appointments
Date:6/14/2010

ainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include, among other things, the following: our ability to progress any product candidates into pre-clinical studies or clinical trials; the scope, initiation, rate and progress of our pre-clinical studies and clinical trials and other research and development activities; clinical trial results; even with positive data from pre-clinical studies or clinical trials, the product candidate may not prove to be safe and efficacious; regulatory approval is needed before any vaccines can be sold in or outside the United States and, to date, no governmental authority has approved any of our vaccine candidates for sale; influenza is seasonal in nature, and if approval or commercial launch after approval is not timely in relation to the influenza season, we may not be able to manufacture or sell our influenza vaccines on terms favorable to us until the next influenza season, if at all; we have not manufactured any of our vaccine candidates at a commercial level; we utilize a unique manufacturing process and the scale-up of that process may prove difficult and/or costly; our dependence on third parties to manufacture and distribute our vaccines; risks associated with conducting business outside of the United States; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equi
'/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/24/2014)... Tenn., July 24, 2014 -- A novel combination of ... Department of Energy,s Oak Ridge National Laboratory an unprecedented ... its unusual physical and electrochemical properties. , The ... oxygen affects the surface of a perovskite manganite, a ... The new avenue to understand surface behavior could benefit ...
(Date:7/24/2014)... worldwide rely on sophisticated equipment, trained personnel, and ... areas against terrorist attacks. A revolutionary new electronic ... make their job much easier. , The groundbreaking ... Tel Aviv University ,s School of Chemistry and ... the Herzliya company Tracense, picks up the scent ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Global Cell Culture Market 2014-2018" report to ... Cell culture is the in vitro growth ... as research, cell studies, and biopharmaceutical production. Cell culture ... production. Cell culture instruments and cell culture consumables are ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2
... DIEGO, March 26 David Koos, Chairman and CEO ... Board: BMSN) announced today that the important discovery reported ... Institutes of Health (NIH; www.nih.gov ), which has ... validates a new direction for stem cell "storage" facilities ...
... (Nasdaq: NVAX ) today announced that it will ... release to be issued after 2:00 p.m. Eastern Time on ... call to discuss its financial results at 4:00 p.m. Eastern ... by Novavax President and Chief Executive Officer Dr. Rahul Singhvi ...
... - Extends Successful Existing Distribution Agreement for the ... Researchers Can Easily Access ZyGEM,s Growing Line of ... DNA Extraction and Is Ideally Suited to Automation ... HAMILTON, New Zealand, March 26 ZyGEM Corp. ...
Cached Biology Technology:NIH News Confirms Trend in Stem Cell 'Storage' Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group 2Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 2Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 3ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 2ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 3ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 4
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
(Date:7/25/2014)... , July 25, 2014 ... consumers are turning to digital technology for online & ... NXTD), Google Inc. (NASDAQ: GOOG ), LifeLock ... V ), Apple Inc. (NASDAQ: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ...
(Date:7/24/2014)... sobering examples of how wildlife loss leads to conflict ... by Wildlife Conservation Society (WCS) Health & Ecosystems: ... calls for an interdisciplinary approach to tackle global biodiversity ... about 15% of the world,s people and provides protein ... It should come as no surprise that today,s unprecedented ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6New study draws links between wildlife loss and social conflicts 2
... mentally, but genetically everyone is very similar. That,s ... But with population research becoming more and more ... concerned that genetic research could awaken racist attitudes. ... geneticist James Watson claimed there are genes responsible ...
... new study by researchers at UC Davis Medical Center ... patients may be a result of their brains not ... drops in blood oxygen levels are more common than ... senior author Masud Seyal, a professor of neurology at ...
... 17, 2008) -- A "chip" or array that can quickly ... with chromosomal abnormalities proved an effective tool in prenatal diagnosis ... Medicine, said researchers in a report that appears in the ... In the report, a team led by Dr. Arthur Beaudet ...
Cached Biology News:Could genetic research awaken racist attitudes? 2Drops in blood oxygen levels may be key to sudden death in some epilepsy patients 2Drops in blood oxygen levels may be key to sudden death in some epilepsy patients 3Microarray analysis improves prenatal diagnosis 2Microarray analysis improves prenatal diagnosis 3
... and Cost effective - Utilizes hands-off homogenization through ... No grinding - Extract DNA without hand ... between samples , Robust tubes - ... homogenize without tube breakage , Flexible ...
A substrate for all AChE-based EIA kits....
... ion trap mass spectrometer enables high-throughput solutions ... LXQ linear ion trap mass spectrometer is ... delivering the fast cycle time and increased ... at an attractive price. The combination ...
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
Biology Products: